Navigation Links
Halozyme to Host Third Quarter 2013 Financial Results Conference Call
Date:11/1/2013

SAN DIEGO, Nov. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013 at 8:30 a.m. ET/5:30 a.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date pre-market, Halozyme will release financial results for the third quarter 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 423197.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on www.twitter.com/HALOTherapeutic.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
2. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
3. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
4. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
5. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
6. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
7. Halozyme Reports Second Quarter 2013 Financial Results
8. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
9. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
10. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) projected ... on May 4, would result in 23 million Americans losing their health insurance by ... Patient Protection and Affordable Care Act (ACA). , “It is clear from the ...
(Date:5/26/2017)... CA (PRWEB) , ... May 26, 2017 , ... Dr. ... is proud to announce a new, informational blog post on insurance options. If a ... checking insurance plans may help save time and money. Visiting an in-network provider for ...
(Date:5/26/2017)... ... ... Jack: Against All Odds”: the story of Coach Cactus Jack and the impact he ... creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and pharmacy ... Walter and Jane have three adult children and a granddaughter. Walter and ...
(Date:5/24/2017)... ... ... Altec Products, Inc., a leader in enterprise document management and ... in San Diego, CA. , At nVerge 2017, Altec will be highlighting ... their Sage ERP solutions by providing improved visibility and control to the entire document ...
(Date:5/24/2017)... ... 24, 2017 , ... STATEMENT OPPOSING PRESIDENT DONALD TRUMP’S 2018 ... Trump’s budget, “A New Foundation for American Greatness—President's Budget FY 2018,” because it ... underserved populations, undermines productivity, and destroys the social safety net needed by hardworking ...
Breaking Medicine News(10 mins):